Skip to main content
SpringerLink
Log in

Lansoprazole for Long-Term Maintenance Therapy of Erosive Esophagitis: Double-Blind Comparison with Ranitidine

  • ORIGINAL ARTICLE
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

In a study evaluating the efficacy and safety of lansoprazole to prevent the relapse of erosive esophagitis (EE), 206 of 241 patients (85%) healed after open-label treatment with lansoprazole 30 mg once daily for 8 weeks and received double-blind maintenance treatment with lansoprazole 15 mg once daily or ranitidine 150 mg twice daily for up to 1 year. At 1 year, 67% of lansoprazole-treated and 13% of ranitidine-treated patients remained healed (P < 0.001). Lansoprazole-treated patients experienced significantly greater symptom relief (P < 0.001), and, if asymptomatic at entry into the maintenance phase, remained asymptomatic for significantly longer than ranitidine-treated patients (P < 0.001). Symptom status correlated with healing (P = 0.001), supporting the symptom-directed management of EE. Both treatments were well tolerated and no unexpected events occurred. Daily therapy with lansoprazole to prevent the relapse of EE is effective, well tolerated, and superior to ranitidine in the maintenance of healing and symptom relief.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion. 1992;51(suppl 1):24–29.

    Article  PubMed  Google Scholar 

  2. McDougall NI, Johnston BT, Kee F, Collins JSA, McFarland RJ, Love AHG. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut. 1996;38:481–486. doi:10.1136/gut.38.4.481.

    Article  PubMed  CAS  Google Scholar 

  3. Heading RC. Review article: diagnosis and clinical investigation of gastro-oesophageal reflux disease. A European view. Aliment Pharmacol Ther. 2004;20(suppl 8):9–13. doi:10.1111/j.1365-2036.2004.02221.x.

    Article  PubMed  Google Scholar 

  4. Ruigomez A, Garcia Rodriguez LA, Wallander MA. Natural history of gastro-oesophageal reflux disease diagnosed in general practice. Aliment Pharmacol Ther. 2004;20:751–760. doi:10.1111/j.1365-2036.2004.02169.x.

    Article  PubMed  CAS  Google Scholar 

  5. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 1999;94:1434–1442. doi:10.1111/j.1572-0241.1999.1123_a.x.

    Article  PubMed  CAS  Google Scholar 

  6. Delaney BC. Review article: prevalence and epidemiology of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004;20(suppl 8):2–4. doi:10.1111/j.1365-2036.2004.02219.x.

    Article  PubMed  Google Scholar 

  7. Holtmann G, Adam B, Liebregts T. Review article: the patient with gastro-oesophageal reflux disease—lifestyle advice and medication. Aliment Pharmacol Ther. 2004;20(suppl 8):24–27. doi:10.1111/j.1365-2036.2004.02224.x.

    Article  PubMed  Google Scholar 

  8. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2004;4:CD003245. doi:10.1002/14651858.CD003245.pub2.

    Google Scholar 

  9. Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. J Clin Outcomes Manag. 2000;7:29–34.

    Google Scholar 

  10. Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006;367:2086–2100. doi:10.1016/S0140-6736(06)68932-0.

    Article  PubMed  Google Scholar 

  11. Peura DA, Lee C, Siepman N, Kovacs TO. Long-term efficacy of symptom-based, titrated dose lansoprazole in preventing relapse of erosive reflux esophagitis in subjects with a recent history of erosive reflux esophagitis. Gastroenterology. 2005;128(suppl 2):A527–A528.

    Google Scholar 

  12. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 1988;95:903–912.

    PubMed  CAS  Google Scholar 

  13. Kovacs TO, Lee CQ, Chiu YL, Pilmer BL, Metz DC. Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis. Aliment Pharmacol Ther. 2004;20(8):883–889. doi:10.1111/j.1365-2036.2004.02188.x.

    Article  PubMed  CAS  Google Scholar 

  14. Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classification of non-antral gastric endocrine growth in man. Digestion. 1988;41:185–200.

    Article  PubMed  CAS  Google Scholar 

  15. Haber M, Amer F, Peura D, Qin Q. Chronic gastritis and erosive esophagitis: prevalence and effect of long-term lansoprazole treatment. Gastroenterology. 2005;128:A527.

    Google Scholar 

  16. Kovacs TOG, Atkinson S, Spalding J, Hunt B. Long-term GERD symptoms and quality-of-life improvement in subjects with healed erosive esophagitis treated for up to 7 years with titrated-dose lansoprazole. Gastroenterology. 2006;130(suppl 2):A454. abstract.

    Google Scholar 

  17. Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol. 2001;96:27–34. doi:10.1111/j.1572-0241.2001.03443.x.

    Article  PubMed  CAS  Google Scholar 

  18. Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. Ann Intern Med. 1996;124:859–867.

    PubMed  CAS  Google Scholar 

  19. Gough AL, Long RG, Cooper BT, Fosters CS, Garrett AD, Langworthy CH. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther. 1996;10:529–539. doi:10.1046/j.1365-2036.1996.14156000.x.

    Article  PubMed  CAS  Google Scholar 

  20. Freston JW, Jackson RL, Huang B, Ballard ED. Lansoprazole for maintenance of remission of erosive oesophagitis. Drugs. 2002;62:1173–1184. doi:10.2165/00003495-200262080-00004.

    Article  PubMed  CAS  Google Scholar 

  21. Adamek RJ, Behrendt J, Wenzel C. Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine. Eur J Gastroenterol Hepatol. 2001;13:811–817. doi:10.1097/00042737-200107000-00009.

    Article  PubMed  CAS  Google Scholar 

  22. Richter JE, Fraga P, Mack M, Sabesin SM, Bochenek W. Prevention of erosive oesophagitis relapse with pantoprazole. Aliment Pharmacol Ther. 2004;20:567–575. doi:10.1111/j.1365-2036.2004.02121.x.

    Article  PubMed  CAS  Google Scholar 

  23. Festen HP, Schenk E, Tan G, Snel P, Nelis F. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group. Am J Gastroenterol. 1999;94:931–936. doi:10.1111/j.1572-0241.1999.989_l.x.

    Article  PubMed  CAS  Google Scholar 

  24. Vakil NB, Shaker R, Johnson DA, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther. 2001;15:927–935. doi:10.1046/j.1365-2036.2001.01024.x.

    Article  PubMed  CAS  Google Scholar 

  25. Pilotto A, Leandro G, Franceschi M, Ageing and Acid-Related Disease Study Group. Short- and long-term therapy for reflux oesophagitis in the elderly: a multi-centre, placebo-controlled study with pantoprazole. Aliment Pharmacol Ther. 2003;17:1399–1406. doi:10.1046/j.1365-2036.2003.01593.x.

    Article  PubMed  CAS  Google Scholar 

  26. Fennerty MB, Johnson DA. Heartburn severity does not predict disease severity in patients with erosive esophagitis. MedGenMed. 2006;8(2):6.

    PubMed  Google Scholar 

  27. Vakil NB, Traxler B, Levine D. Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment. Clin Gastroenterol Hepatol. 2004;2(8):665–668. doi:10.1016/S1542-3565(04)00289-7.

    Article  PubMed  CAS  Google Scholar 

  28. Pilotto A, Franceschi M, Leandro G, et al. Clinical features of reflux esophagitis in older people: a study of 840 consecutive patients. J Am Geriatr Soc. 2006;54(10):1537–1542. doi:10.1111/j.1532-5415.2006.00899.x.

    Article  PubMed  Google Scholar 

  29. DeVault KR, Morgenstern DM, Lynn RB, Metz DC. Effect of pantoprazole in older patients with erosive esophagitis. Dis Esophagus. 2007;20:411–415. doi:10.1111/j.1442-2050.2007.00642.x.

    Article  PubMed  CAS  Google Scholar 

  30. Annibale B, Franceschi M, Fusillo M, Beni M, Cesana B, Delle Fave G. Omeprazole in patients with mild or moderate reflux esophagitis induces lower relapse rates than ranitidine during maintenance treatment. Hepatogastroenterology. 1998;45(21):742–751.

    PubMed  Google Scholar 

  31. DeVault KR, Johanson JF, Johnson DA, Liu S, Sostek MB. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clin Gastroenterol Hepatol. 2006;4:852–859. doi:10.1016/j.cgh.2006.03.006.

    Article  PubMed  Google Scholar 

  32. Wiklund I, Bardhan KD, Müller-Lissner S, et al. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omperazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group. Ital J Gastroenterol Hepatol. 1998;30(1):19–27.

    PubMed  CAS  Google Scholar 

  33. Hansen AN, Bergheim R, Ageratums H, Lund H, Wiklund I, Moum B. Long-term management of patients with symptoms of gastro-oesophageal reflux disease—a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners setting. Int J Clin Pract. 2006;60(1):15–22. doi:10.1111/j.1368-5031.2006.00768.x.

    Article  PubMed  CAS  Google Scholar 

  34. Oster G, Thompson D, Katz S, et al. The GORD outcomes trial: a randomized study to assess outcomes and costs in primary care practice. Gastroenterology. 1998;114:A32. doi:10.1016/S0016-5085(98)80130-3. abstract.

    Article  Google Scholar 

  35. Kaplan-Machlis B, Spiegler GE, Zodet MW, Revicki DA. Effectiveness and costs of omeprazole vs. ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. Arch Fam Med. 2000;9(7):624–630. doi:10.1001/archfami.9.7.624.

    Article  PubMed  CAS  Google Scholar 

  36. Matheson AJ, Jarvis B. Lansoprazole: an update of its place in the management of acid-related disorders. Drugs. 2001;61:1801–1833. doi:10.2165/00003495-200161120-00011.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This study (M94-140) was funded by Takeda Global Research & Development Center, Inc., Deerfield, IL, USA (TAP Pharmaceutical Products Inc. is now part of Takeda Global Research & Development Center, Inc.). Editorial support for the preparation of this article was provided by Rx Communications (UK). Dr. Peura is a consultant for Takeda Global Research & Development Center, Inc., and is a member of the speaker’s bureau for Takeda Pharmaceuticals North America, Inc., Astra Zeneca, and Santarus. Dr. Freston serves as a consultant for Takeda Global Research & Development Center, Inc., Takeda Pharmaceuticals North America, Inc., GlaxoSmithKline, and EnteroMedics Inc. Dr. Haber is a consultant for Takeda Global Research & Development Center, Inc. Dr. Kovacs confirms that he has no conflicts of interest or disclosures.

Author information

Authors and Affiliations

  1. University of Virginia Health System, Charlottesville, VA, 22908-0708, USA

    David A. Peura

  2. University of Connecticut Health Center, Farmington, CT, USA

    James W. Freston

  3. Department of Pathology, Drexel University College of Medicine, Philadelphia, PA, USA

    Marian M. Haber

  4. VA Greater LA Healthcare System, CURE Clinic, Los Angeles, CA, USA

    Thomas O. Kovacs

  5. Takeda Global Research & Development Center, Inc., Deerfield, IL, USA

    Barbara Hunt & Stuart Atkinson

Authors
  1. David A. Peura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James W. Freston
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marian M. Haber
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas O. Kovacs
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Barbara Hunt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stuart Atkinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David A. Peura.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peura, D.A., Freston, J.W., Haber, M.M. et al. Lansoprazole for Long-Term Maintenance Therapy of Erosive Esophagitis: Double-Blind Comparison with Ranitidine. Dig Dis Sci 54, 955–963 (2009). https://doi.org/10.1007/s10620-008-0466-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-008-0466-9

Keywords

Search

Navigation